Entera Bio Ltd. — Director's Dealing 2024

Aug 2, 2024

SEC Form 4/A — Form 4/A

Issuer: Entera Bio Ltd. (ENTX)
CIK: 0001638097
Period of Report: 2024-04-19

Reporting Person: Yaacov-Garbeli Dana (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-04-19	Ordinary Shares, par value NIS 0.0000769 per share	A	30151	—	Acquired	86731	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-04-19	Stock Option (right to buy)	$1.99	A	130000	Acquired	2034-04-19	Ordinary Shares, par value NIS 0.0000769 per share (130000)	Direct

Footnotes

F1: Represent a grant of stock-settled restricted stock units. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on April 19, 2024.

F2: On April 23, 2024, the reporting person filed a Form 4 which inadvertently reported that the reporting person's ordinary shares and restricted stock units are held directly.

F3: These shares are owned by A2Z Counseling Ltd. of which the reporting person owns a 33.33% interest and has effective control over voting and disposition of the shares. The reporting person disclaims beneficial ownership of the securities held by A2Z Counseling Ltd., except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that she is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

F4: The options vest over a three-year period with 33% of the options vesting on April 19, 2025, the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining two-year period.